On Monday shares of Calithera Biosciences, Inc. (NASDAQ:CALA) closed at $18.74. Company’s EPS growth for next 5 years is recorded as 75.00%. Calithera Biosciences, Inc. (NASDAQ:CALA), announced that the Company’s fourth quarter and year-end 2014 financial results will be released on Thursday, March 26, 2015.
ImmunoGen, Inc. (NASDAQ:IMGN) in last trading activity increased 16.80% to close at $8.69. Company weekly performance is 12.86% while its quarterly performance stands at -19.91%. ImmunoGen, Inc. (NASDAQ:IMGN) is -48.18% away from its 52 week high. ImmunoGen, Inc. (NASDAQ: IMGN), announced the presentations on Company and partner programs to be made at the upcoming American Association for Cancer Research (AACR) annual meeting to be held April 18-22, 2015 in Philadelphia, PA.
On last trading day NephroGenex, Inc. (NASDAQ:NRX) increased 12.82% to close at $8.36. Its volatility for the week is 8.52% while volatility for the month is 8.65%. NephroGenex, Inc. (NASDAQ:NRX) monthly performance is 32.70%. NephroGenex, Inc. (NASDAQ: NRX), will report its fourth quarter and full year 2014 financial results on Tuesday, March 24, 2015 after the U.S. financial markets close.
PhotoMedex, Inc. (NASDAQ:PHMD) has 22.60% insider ownership while its institutional ownership stands at 36.60%. In last trading activity company’s stock closed at $1.96. Shepherd, Finkelman, Miller & Shah, LLP announces that the United States District Court for the Eastern District of Pennsylvania has approved the following announcement of a proposed class action settlement that would benefit purchasers of PhotoMedex, Inc. securities (NASDAQ: PHMD).
On last trading day Kamada Ltd. (NASDAQ:KMDA) increased 8.94% to close at $4.63. Its volatility for the week is 4.03% while volatility for the month is 3.32%. Kamada Ltd. (NASDAQ:KMDA) monthly performance is 1.31%. Kamada Ltd. (NASDAQ:KMDA) announces that the European Commission, acting on the recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA), has designated the Company’s proprietary human intrevenous (IV) Alpha-1 Antitrypsin (AAT) as an orphan medicinal product to treat Graft-versus-host disease (GvHD). In October 2014 Kamada received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for its AAT by IV to treat GvHD.